Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1993 Dec;70(6):537–541. doi: 10.1136/hrt.70.6.537

Primary pulmonary hypertension and fenfluramine use.

F Brenot 1, P Herve 1, P Petitpretz 1, F Parent 1, P Duroux 1, G Simonneau 1
PMCID: PMC1025385  PMID: 8280518

Abstract

Not all the risk factors for primary pulmonary hypertension (PPH) are known. Appetite suppressants, including fenfluramine derivatives, are strongly suspected aetiological agents. In a 5 year retrospective study fenfluramine use was evaluated among patients referred to a medical centre specialising in the management of PPH. Fifteen (20%) of 73 patients with PPH had used fenfluramine: all of them were women and in 10 (67%) there was a close temporal relation between fenfluramine use and the development of exertional dyspnoea. Initial right heart catheterisation in the 15 women showed severe resting pulmonary hypertension (mean (SD)) with pulmonary artery pressure (PAP) 57 (9) mm Hg, cardiac index 2.1 (0.5) l/min/m2, and pulmonary vascular resistance (PVR) 29 (10) U/m2. Short-term epoprostenol infusion produced a significant vasodilator response in 10 patients (mean fall in PVR 24 (15%) compared with control values). Three fenfluramine users with PPH showed spontaneous clinical and haemodynamic improvement 3, 6 and 12 months after drug withdrawal but there was no significant difference in overall survival (transplant recipients excluded) between fenfluramine users and controls. Histological examination of lung tissue from five women who had used fenfluramine and 22 controls, with PPH showed features typical of advanced plexogenic pulmonary arteriopathy in all. These results do not accord with earlier reports that PPH associated with fenfluramine is less severe and has a better outcome. Fenfluramine may be one aetiological agent that can precipitate or hasten the development of PPH. The results of a European case-control study should give new insights into risk factors for PPH and the cause and effect relation with fenfluramine.

Full text

PDF
539

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Douglas J. G., Munro J. F., Kitchin A. H., Muir A. L., Proudfoot A. T. Pulmonary hypertension and fenfluramine. Br Med J (Clin Res Ed) 1981 Oct 3;283(6296):881–883. doi: 10.1136/bmj.283.6296.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gaul G., Blazek G., Deutsch E., Heeger H. Ein Fall von chronischer pulmonaler Hypertonie nach Fenfluramineinnahme. Wien Klin Wochenschr. 1982 Nov 26;94(22):618–622. [PubMed] [Google Scholar]
  3. Gurtner H. P., Gertsch M., Salzmann C., Scherrer M., Stucki P., Wyss F. Häufen sich die primär vasculären Formen des chronischen Cor pulmonale? Schweiz Med Wochenschr. 1968 Oct 12;98(41):1579–contd. [PubMed] [Google Scholar]
  4. Gurtner H. P. Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter? Bull Eur Physiopathol Respir. 1979 Sep-Oct;15(5):897–923. [PubMed] [Google Scholar]
  5. Hunsinger R. N., Wright D. A characterization of the acute cardiopulmonary toxicity of fenfluramine in the rat. Pharmacol Res. 1990 May-Jun;22(3):371–378. doi: 10.1016/1043-6618(90)90735-v. [DOI] [PubMed] [Google Scholar]
  6. Loogen F., Worth H., Schwan G., Goeckenjan G., Lösse B., Horstkotte D. Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa. 1985;27(2-3):111–124. [PubMed] [Google Scholar]
  7. Marine W. M., Gurr D., Jacobsen M. Clinically important respiratory effects of dust exposure and smoking in British coal miners. Am Rev Respir Dis. 1988 Jan;137(1):106–112. doi: 10.1164/ajrccm/137.1.106. [DOI] [PubMed] [Google Scholar]
  8. McGoon M. D., Vanhoutte P. M. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest. 1984 Sep;74(3):828–833. doi: 10.1172/JCI111499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. McMurray J., Bloomfield P., Miller H. C. Irreversible pulmonary hypertension after treatment with fenfluramine. Br Med J (Clin Res Ed) 1986 Jan 25;292(6515):239–240. doi: 10.1136/bmj.292.6515.239-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Nemecek G. M., Coughlin S. R., Handley D. A., Moskowitz M. A. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A. 1986 Feb;83(3):674–678. doi: 10.1073/pnas.83.3.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Overgaard K., Hansen M. A., Nielsen V. A., Riis B. J., Christiansen C. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. Am J Med. 1990 Jul;89(1):1–6. doi: 10.1016/0002-9343(90)90089-v. [DOI] [PubMed] [Google Scholar]
  12. Pinder R. M., Brogden R. N., Sawyer P. R., Speight T. M., Avery G. S. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs. 1975;10(4):241–323. doi: 10.2165/00003495-197510040-00001. [DOI] [PubMed] [Google Scholar]
  13. Polos P. G., Wolfe D., Harley R. A., Strange C., Sahn S. A. Pulmonary hypertension and human immunodeficiency virus infection. Two reports and a review of the literature. Chest. 1992 Feb;101(2):474–478. doi: 10.1378/chest.101.2.474. [DOI] [PubMed] [Google Scholar]
  14. Pouwels H. M., Smeets J. L., Cheriex E. C., Wouters E. F. Pulmonary hypertension and fenfluramine. Eur Respir J. 1990 May;3(5):606–607. [PubMed] [Google Scholar]
  15. Rich S., Dantzker D. R., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., Fishman A. P., Goldring R. M., Groves B. M., Koerner S. K. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987 Aug;107(2):216–223. doi: 10.7326/0003-4819-107-2-216. [DOI] [PubMed] [Google Scholar]
  16. Roche N., Labrune S., Braun J. M., Huchon G. J. Pulmonary hypertension and dexfenfluramine. Lancet. 1992 Feb 15;339(8790):436–437. [PubMed] [Google Scholar]
  17. Rubin L. J., Groves B. M., Reeves J. T., Frosolono M., Handel F., Cato A. E. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982 Aug;66(2):334–338. doi: 10.1161/01.cir.66.2.334. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES